Keryx Biopharmaceuticals


Keryx Biopharmaceuticals: This Analyst Blames Slowing Script Growth for Bad Q3 Outcome

Keryx Biopharmaceuticals (NASDAQ:KERX) has commercial adoption challenges ahead for its iron deficiency anemia asset Auryxia, says Cowen analyst Boris Peaker. After the company’s …

Biotech Bulletin of the Week: Gilead Sciences, Inc. (GILD), Vertex Pharmaceuticals Incorporated (VRTX), and Keryx Biopharmaceuticals (KERX)

Gilead’s FDA-Approved Drug Still Faces an Uphill Battle in HCV Ring Gilead Sciences, Inc. (NASDAQ:GILD) just scored a green light from the FDA …

Stock Update (NASDAQ:KERX): Keryx Biopharmaceuticals Announces the Largest Medicare Part D Plan Sponsor Added Auryxia to its Medicare Part D Plan Formularies

Keryx Biopharmaceuticals (NASDAQ:KERX) announced that the nation’s largest Medicare Part D plan sponsor has added Auryxia® (ferric citrate) to its Medicare Part D …

Keryx Biopharmaceuticals (KERX): Focusing On Auryxia Growth

Maxim analyst Jason McCarthy is out today with a new research note on shares of Keryx Biopharmaceuticals (NASDAQ:KERX), after the drug maker reported fourth quarter …

Keryx Biopharmaceuticals (KERX) Reports 4Q and Full Year 2016 Results

Keryx Biopharmaceuticals (NASDAQ:KERX) announced its financial results for the fourth quarter and year ended December 31, 2016. The company also reviewed its commercial …

Company Update (NASDAQ:KERX): Keryx Biopharmaceuticals Announces Publication of Auryxia Phase 3 Trial Results in JASN

Keryx Biopharmaceuticals (NASDAQ:KERX) announced the publication of results from its pivotal Phase 3 study evaluating ferric citrate for iron deficiency anemia (IDA) in …

Company Update (NASDAQ:KERX): Keryx Biopharmaceuticals Announces Case Study Data of Auryxia® Presented at ASN’s Kidney Week

Keryx Biopharmaceuticals (NASDAQ:KERX) announced case study data, which showed that Auryxia® (ferric citrate) lowered and maintained serum phosphorus levels in chronic kidney disease …

Company Update (NASDAQ:KERX): Keryx Biopharmaceuticals Announces Presentations of Phase 3 Trial Results of Ferric Citrate for IDA in Non-Dialysis Dependent Chronic Kidney Disease

Keryx Biopharmaceuticals (NASDAQ:KERX) announced presentation of additional data from its pivotal Phase 3 study for iron deficiency anemia (IDA) and non-dialysis dependent chronic …

FBR Weighs in on Keryx Biopharmaceuticals (KERX) as FDA Approves Second CMO for Auryxia

FBR Capital analyst Christopher James weighed in with a few insights on Keryx Biopharmaceuticals (NASDAQ:KERX), after the drug maker announced that the FDA granted approval for …

Company Update (NASDAQ:KERX): Here’s Why Keryx Biopharmaceuticals Shares Rose 12% Today

Keryx Biopharmaceuticals (NASDAQ:KERX) investors have a smile on their faces Wednesday, after the drug maker announced that the FDA has approved its application …